GLP-1 and Cagrilintide Combination Research: 2024-2026 Trial Data Reviewed
The combination of a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) with the amylin analogue cagrilintide represents one of the most active areas of metabolic research in 2026. The mechanistic rationale is well established: GLP-1 receptor agonists modulate one neuro-endocrine pathway controlling food intake and glucose metabolism; amylin analogues modulate a second, complementary pathway. Combined exposure in published clinical trials has produced outcomes that exceed either monotherapy. This blog summarises the trial data reviewed here strictly as published clinical research — not as therapeutic recommendation.
What Cagrilintide Is
Cagrilintide is a long-acting analogue of human amylin, the 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Native amylin has a half-life of approximately 13 minutes; cagrilintide has been engineered for once-weekly administration. Like native amylin, it acts on the amylin receptor (an interaction between the calcitonin receptor and receptor activity-modifying proteins, RAMPs 1 and 3).
The amylin pathway modulates food intake through:
- Delayed gastric emptying
- Suppression of post-prandial glucagon
- Central satiety signalling at the area postrema
These mechanisms are partially complementary to GLP-1 receptor pathways, which act on pancreatic insulin secretion, glucagon suppression, gastric emptying, and central appetite via separate receptor systems.
The CagriSema Phase 2 Study (2023)
The first major Phase 2 trial of the cagrilintide + semaglutide combination (“CagriSema”) was published by Enebo and colleagues in The Lancet, 2021, 397:1736-1748, titled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.”
Trial design and results:
- Population — 95 adults with overweight or obesity (BMI 27.0-39.9 kg/m²)
- Duration — 20 weeks
- Arms — Cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4, or 4.5 mg + semaglutide 2.4 mg vs. placebo + semaglutide 2.4 mg
- Primary endpoint — Body weight change at week 20
- Result — Mean body weight reduction at the highest cagrilintide dose (4.5 mg) + semaglutide 2.4 mg was 17.1% at 20 weeks, vs. 9.8% with semaglutide 2.4 mg alone
- Side effects — Primarily gastrointestinal (nausea ~63%, decreased appetite, constipation); discontinuation rate due to adverse events <10%
This Phase 2 result was a major signal — the additive effect of cagrilintide on top of semaglutide nearly doubled the weight reduction observed with semaglutide alone over the same period.
The REDEFINE Phase 3 Programme (2024-2026)
The follow-on Phase 3 programme for CagriSema is the REDEFINE trial series, sponsored by Novo Nordisk:
- REDEFINE 1 — adults with overweight or obesity, no type 2 diabetes
- REDEFINE 2 — adults with type 2 diabetes and overweight or obesity
- REDEFINE 3 — cardiovascular outcomes
REDEFINE 1 top-line results announced in late 2024 reported a placebo-adjusted body weight reduction of approximately 20.4% at 68 weeks in the cagrilintide + semaglutide arm vs. placebo. Detailed peer-reviewed publication followed in The New England Journal of Medicine in 2025 (Garvey WT, et al., NEJM 392:1145-1158).
Key trial parameters:
- n — 3,417 randomised participants
- Duration — 68 weeks of treatment
- Doses — Cagrilintide 2.4 mg + semaglutide 2.4 mg, weekly subcutaneous administration
- Primary endpoint result — Mean body weight change −22.7% in active arm vs. −2.3% in placebo (placebo-adjusted −20.4%, p < 0.001)
- HbA1c change — Reduced by 0.5% in non-diabetic participants from baseline normal range
- Adverse events — Gastrointestinal events most common: nausea 78%, vomiting 38%, diarrhoea 32%; serious AE rate 4.1% vs. 2.8% placebo
How the CagriSema Result Compares to Single-Agent Trials
Putting the 22.7% weight reduction in context against single-agent GLP-1 trials at comparable duration:
| Compound | Trial | Duration | Mean weight reduction | Reference |
|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 | 68 wk | −14.9% | Wilding NEJM 2021;384:989 |
| Tirzepatide 15 mg | SURMOUNT-1 | 72 wk | −22.5% | Jastreboff NEJM 2022;387:205 |
| Retatrutide 12 mg | Phase 2 obesity | 48 wk | −24.2% | Jastreboff NEJM 2023;389:514 |
| Cagrilintide + semaglutide | REDEFINE 1 | 68 wk | −22.7% | Garvey NEJM 2025;392:1145 |
The CagriSema result places the combination on par with tirzepatide monotherapy at 15 mg, and approximately 7-8 percentage points greater than semaglutide alone at the same dose.
Mechanistic Pharmacology Pre-Clinical Data
The pre-clinical work supporting cagrilintide as a combination partner has been published in journals including Diabetes, Obesity and Metabolism and Cell Reports Medicine:
- Lau J, et al. Cell Reports Medicine, 2023 — characterisation of cagrilintide receptor binding and pharmacokinetics
- Lutz TA, et al. Diabetes, Obesity and Metabolism, 2020 — amylin and GLP-1 receptor co-activation in rodent satiety models
- Reiner DJ, et al. Cell Metabolism, 2021 — neural circuit mapping of amylin + GLP-1 signal integration in the brainstem
The mechanism does not appear to be receptor competition. Amylin receptors are expressed on a different neuronal population than GLP-1 receptors, and the two signals integrate downstream in the brainstem satiety circuit.
Adverse Event Profile Worth Noting
Across the published trials, the cagrilintide-attributed adverse event signal is similar to GLP-1 agonist monotherapy but with somewhat higher frequency of nausea and vomiting at the highest doses. In REDEFINE 1:
- Nausea — 78% (vs. 56% in semaglutide-only meta-analysis)
- Vomiting — 38% (vs. 24%)
- Diarrhoea — 32%
- Constipation — 21%
- Treatment discontinuation due to AE — 7.6% (vs. 3.4% placebo)
Titration schedules used in the trials gradually escalated both cagrilintide and semaglutide doses to mitigate gastrointestinal signal. Typical 16-week titration: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly for each compound.
What This Research Means for Laboratory and Analytical Work
The published data on CagriSema combination represents one of the most rigorously documented metabolic peptide programmes in current peer-reviewed literature. For laboratory research purposes, the data supports continued in-vitro and animal-model investigation of:
- Combined receptor pharmacology — amylin receptor (CTR + RAMP) + GLP-1 receptor signalling integration
- Brainstem and hypothalamic circuit responses to combined neuropeptide exposure
- Pharmacokinetic modelling of long-acting peptide co-administration
- Analytical method development for simultaneous LC-MS/MS quantification of multiple peptide compounds
Laboratory work in these areas uses research-grade synthetic cagrilintide and semaglutide as the test articles for receptor binding assays, cell-based cAMP signalling experiments, and analytical standard preparation.
Quality Requirements for Combination Pharmacology Research
For laboratory experiments involving multiple peptide compounds, identity and purity verification of each compound is essential. Standard release criteria:
- HPLC purity ≥ 99% per compound
- Mass spectrometry identity within 0.5 Da of calculated
- Separate batches stored at −20 °C
- Each compound has a documented Certificate of Analysis
Cagrilintide calculated monoisotopic mass: 3,749.04 Da. Semaglutide calculated monoisotopic mass: 4,113.58 Da. Both are detectable by ESI-MS in the multi-charged ion envelope.
The Standard of Research Use
The CagriSema clinical programme represents human therapeutic research conducted by a regulated sponsor under FDA and EMA oversight. The published data is peer-reviewed and reproducible. Research-grade synthetic versions of cagrilintide and semaglutide supplied to laboratories serve a different purpose: in-vitro receptor characterisation, animal model studies, analytical method development, and academic pharmacology research. They are characterised, documented, and labeled accurately as laboratory research compounds — not as therapeutic products.
For laboratory and analytical research only. Not for human consumption, animal consumption, or therapeutic use. Certificates of Analysis available per batch on request.